NOTCH PATHWAY MUTATION CONTRIBUTES TO INFERIOR PROGNOSIS IN HBV‐INFECTED CHRONIC LYMPHOCYTIC LEUKEMIA

Chronic lymphocytic leukemia (CLL) patients with hepatitis B virus (HBV) infection have a poor prognosis, underlying mechanism remains unclear. NOTCH mutations are frequent in CLL and associated disease progression drug resistance. It is also reported to be lymphoid malignancies. In order investigate the relation between pathway HBV-associated CLL, we studied 98 previously untreated HBV positive 244 HBV-negative CLL. A total of 342 treatment naïve diagnosed at First Affiliated Hospital Nanjing Medical University from 1 January 2010 31 October 2021 were enrolled our study. The mutation hotspots genes analyzed by Next Generation Sequencing (NGS) DNA that used PCR for identification genomic mutation. Fisher exact χ2 tests assess correlation clinical, demographic factors patients. Survival curves generated Graphpad 9.5. more subgroup (17.3% vs. 7.4%, p = 0.033). By survival analysis, was (p 0.0099 overall [OS] 0.0446 time-to-treatment [TTT]). Any lesions (NOTCH1, NOTCH2 SPEN) aggravated prognosis. multivariate retained an independent significance HBV-infected 0.016 OS 0.023 TTT). However, unmutated had no statistical difference prognosis compared negative 0.1706 0.2387 TTT), which indicated contributed inferior conclusion, cohort displayed worse clinical outcome status signaling might play crucial role. Keywords: chronic (CLL), diagnostic prognostic biomarkers No conflicts interests pertinent abstract.